Medicine and Healthcare
Endocarditis After Valve Replacement
World's largest study reveals risks
Scientific name of the study
Nationwide Registry-Based Analysis of Infective Endocarditis Risk After Pulmonary Valve Replacement
Individuals with congenital heart defects have a higher risk of developing infective endocarditis than heart-healthy people. The inflammation of the inner lining of the heart and the heart valves is dangerous. In some cases, endocarditis is lethal despite treatment. The disease, which is usually caused by bacteria or, more rarely, by fungi, is also one of the more frequent complications following pulmonary valve replacement. About one in ten congenital heart defects requires at least one such procedure. A nationwide study has comprehensively investigated the risk of endocarditis after valve replacement for the first time.
-
Good to know
What Happens During Pulmonary Valve Replacement?
The pulmonary valve connects the right ventricle of the heart to the pulmonary artery. It allows deoxygenated blood to flow from the heart into the pulmonary circulation so that it can once again take up enough oxygen in the lungs to supply the body. When the pulmonary valve needs to be replaced, this can be done either through surgery or catheter intervention. In catheter intervention, the valve is delivered to the heart via a blood vessel and inserted there. A variety of pulmonary valve replacements are available, differing in material and design. The valves are either derived from a human organ donor (homografts) or from an animal (heterografts) or are made of artificial material (mechanical valves). Because no valve replacement can yet grow with the heart and because it often no longer functions well after a few years due to constant strain, it must be replaced over time, depending on its type and the age of the patient. This requires a new operation or intervention.
collapse
Largest retrospective analysis worldwide
The research team e medical records of 1,170 participants aged 0 to 81 years in the National Registry who had received at least one pulmonary valve replacement. Over an average of 10 years per patient, the researchers observed how age, gender, frequency of pulmonary valve replacement, timing and type of procedure, and types of valves used affected the risk of developing endocarditis.
"Previous findings on this were based on data from comparatively small cohorts. With the support of the National Registry and the Competence Network for Congenital Heart Defects, we were able to follow up for the first time in a broad proportion of the population how patients' health developed after valve implantation by catheter intervention or surgery," explains Clara Stammnitz, who conducted th study as all part of her doctoral thesis. During the observation period, data from 1,598 pulmonary valve replacement surgeries were analyzed. All cases of endocarditis associated with pulmonary valve replacement between 2007 and 2017 were recorded.
Valve replacement from bovine jugular vein valve poses special risk
The study showed that there are three main risk factors involved in infective endocarditis. Male patients had an increased risk of developing endocarditis compared with female patients. This risk increased further after a higher number of required valve replacement implantations per patient. However, the timing and type of surgery or intervention and the size of the implant did not play a role. In contrast, biological pulmonary valve replacements made from jugular bovine material posed a particular risk. "The use of Contegra and Melody valves was associated with an increased incidence of endocarditis," says Clara Stammnitz.
-
Results in numbers
Every twentieth patient developed endocarditis
Overall, 4.8 percent of all patients after pulmonary valve replacement developed endocarditis. Of those under the age of 18, the figure was as high as 5.3 percent. About one third of the cases were caused by staphylococci, followed by streptococci as the second most common pathogen.
After homograft implantation, seven of 558 patients developed endocarditis caused by infection. This represents 1.3 percent. Of 723 patients who received a heterograft implant, 4.3 percent, or 31 in numbers, developed endocarditis. And 7.5 percent (18 of 241) developed disease after Melody valve implantation. In contrast, no endocarditis occurred with Edwards-Sapien valves and mechanical valves, which were used less frequently overall, however.
The risk of endocarditis was equally increased with Contegra valves and Melody valves. Both biological valves are composed of jugular venous valve material and were most frequently associated with the development of endocarditis, regardless of their mode of deployment, either surgically or by catheter intervention.
collapse
However, Sabine Klaassen says that further research is needed into the causes. "Since the results did not show any difference in the risk of endocarditis between patients with surgical and interventional valve replacements, we assume that the increased incidence of endocarditis in Contegra and Melody valves is related to the origin of the bovine material of these valve types, specifically the jugular venous valve. At the same time, it was shown that the risk of disease increases with the number of necessary reoperations," continued the study author and Charité physician. The valve replacements from human donors (homografts) and the majority of valve replacements from different animal materials (heterografts), including bovine pericardial derived tissue, showed a very low risk of infection.
-
Scientific Details of the Study
This study was considered in the ESC 2023 Guidelines for the management of endocarditis.
Learn more about the study design, material and methods, as well as the background of the study:
Publications
-
18.2.2022
Nationwide Registry-Based Analysis of Infective Endocarditis Risk After Pulmonary Valve Replacement.
Stammnitz C, Huscher D, Bauer UMM, Urban A, Nordmeyer J, Schubert S, Photiadis J, Berger F, Klaassen S, German Competence Network for Congenital Heart Defects Investigators ,
Journal of the American Heart Association 11, 5, e022231, (2022). Show this publication on PubMed.
-